Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 4Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Oropharyngeal Neoplasms 2Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 11Fluorouracil 10Capecitabine 9Leucovorin 7Radiotherapy 6Nivolumab 6Cetuximab 5Magnetic Resonance Spectroscopy 4Specimen Handling 3Radiation 3Bevacizumab 3sintilimab 2pembrolizumab 2fludarabine 2encorafenib 2dostarlimab 2aldesleukin 2Trastuzumab 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sigmoidoscopy 2Radiotherapy, Intensity-Modulated 2Pemetrexed 2Magnetic Resonance Imaging 2Irinotecan 2Gemcitabine 2Folfox protocol 2Endoscopy 2Electrocardiography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × (225)Ac-DOTA-c(RGDyK) × 30 days × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡